Margaretta Colangelo on Longevity2020

An in-depth preview of big-hitting AI speakers at the first ever online Longevity conference.

It’s finally here – Longevity2020 week has arrived! Later today, we get things going with our first session Defining biological aging, followed by a different theme every day this week. To kick things off, we wanted to share a guest post from the wonderful Margaretta Colangelo, co-founder and managing partner at Deep Knowledge Ventures. A huge thank you to Margaretta, who was instrumental in helping us put together the conference programme, and we look forward to her Wednesday session on AI & Longevity.

Note that Margaretta’s post first appeared on LinkedIn: https://www.linkedin.com/pulse/next-week-longevity2020-first-global-online-longevity-colangelo/

This week, Longevity experts from around the world will come together for Longevity2020 the first worldwide online Longevity conference. Scientists, investors, and CEOs will share the latest research, innovations, and opinions. The conference will run over 5 days and include presentations, fireside chats, and Q&A sessions. At the end of each session there will be ‘ask me anything’ sessions with speakers which provides a unique opportunity to network with the key players in the Longevity sector. To register for Longevity2020 please go to the Longevity Technology website.

On Wednesday we will kick off the AI for Longevity Program with a conversation with three scientists who are applying AI and big data analytics for healthy longevity. We will speak with John Shepherd, PhD, Richard Siow, PhD, and Alex Zhavoronkov, PhD. John Shepherd PhD is co-founder of the AI Precision Health Institute (AI-PHI) at the University of Hawai‘i Cancer Center. Dr. Shepherd and his team are using AI and machine learning to quantify human health and predict risk of disease. Dr. Shepherd will discuss how he and his team use AI to analyze body composition to predict risk of disease, fractures, and frailty. The AI-PHI is conducting population based and laboratory based research to determine how ethnic, cultural, and environmental factors impact human health. Since Hawaii has one of the most diverse populations in the world, it’s an ideal place to study how genetic susceptibility interacts with environmental factors to impact health. Research conducted at the AI-PHI is unique and can only been done in Hawaii because Hawaii has the longest life expectancy and the most ethnic diversity of any state in the US. (Image of the interior of the AI-PHI).

We will discuss how AI is used in medical imaging and stem cell biology with Richard Siow PhD, Director of the Longevity AI Consortium (LAIC), at Kings College London. AI for Longevity is an underrepresented sector in the Longevity Industry despite having more potential to increase Healthy Longevity in the short term than any other sector.

The LAIC will work to facilitate the shift from treatment to prevention and from preventive medicine to real-world precision health. The initial aim will be to identify novel longevity and healthy ageing biomarkers to accelerate diagnosis of age-related health decline. Then researchers will develop personalized physical, mental and financial health to better implement and promote healthy lifestyles for longevity, such as modifying patterns in sleep, nutrition, physical activity, environmental exposure, and financial planning.

The Consortium will use King’s world-leading advances in genetics, AI, and aging research to develop advanced personalized diagnostics, prognostics, and therapeutic benchmarking developed by Aging Analytics Agency. King’s College London was the logical choice of location for the first Longevity AI Consortium, due to their unique combination of resources, departments, and technologies for both AI and Longevity. The Consortium launched with strategic and financial support from Deep Knowledge Ventures and The Biogerontology Research Foundation.

The Longevity AI Consortium is based at King’s College London.
We will also speak with Alex Zhavoronkov, PhD, CEO of Insilico Medicine and chief scientist of the Biogerontology Research Foundation. Insilico Medicine is applying the latest advances in AI to drug discovery, biomarker development, and aging research. The Biogerontology Research Foundation is the UK’s leading non-profit focused on Longevity and Aging research. The Foundation has supported multiple initiatives relating to advancing Healthy Longevity. It provided financial and organizational support to Longevity International UK for the purpose of establishing the UK All-Party Parliamentary Group for Longevity, and to Ageing Research at King’s for the purpose of establishing the Longevity AI Consortium at King’s College London. The Foundation was also actively involved in the successful initiative to add a new extension code for “ageing-related diseases” accepted in 2018 by the World Health Organization during the last revisions of its International Classification of Diseases framework.

On Thursday, Dmitry Kaminskiy will speak in the Longevity Investing Program about global pandemics and accelerated investment in Longevity. Dmitry Kaminskiy is an investor active in the fields of Longevity, Precision Medicine, and AI. He is co-founder and managing partner at Deep Knowledge Ventures, a leading investment fund focused on DeepTech, known for its use of sophisticated analytical systems for investment target identification and due-diligence. He was instrumental at the initial stage of the launch of the All-Party Parliamentary Group for Longevity in the UK Parliament and now serves as co-director of the secretariat, overseeing the APPG’s international Longevity cooperation development division. He is also supervising all of the APPG’s activities related to the development of Centers of AI for Preventive Medicine in the UK.

Dmitry adheres to the principal of Impact Investing, believing that business should intentionally make a significant impact for social good. He operates according to the maxim that business should be aligned with societal good and humanitarianism, and his activities in both business and the non-profit sector are aimed at the shared goal of advancing exponential and disruptive technologies to accelerate positive paradigm shifts in finance, healthcare, and AI.

Program Overview

Monday – Defining Biological Aging

On Monday, the Defining Biological Aging Program will address the need for candidate definitions from different biological, clinical, logical and computational angles to adopt a consensus definition for biological aging, and more.

Tuesday- Rejuvenation Therapies

On Tuesday, the Rejuvenation Therapies Program will explore senolytics, gene editing, peptides, stem cells, immunotherapy, mitochondrial restoration, and neutraceuticals, and more.

Wednesday – AI and Longevity

On Wednesday in the AI and Longevity Program AI experts will discuss AI in medical imaging, AI in stem cells, AI in precision health, molecule identification, pre-clinical validation, digital health, lifestyle interventions, and more.

Thursday – Longevity Investing

On Thursday, in the Longevity Investing Program, Longevity investors will discuss investment platforms, risk management, and emerging technologies including 3D bio-printing, neuroceuticals, organ growth, Agetech, and more.

Friday – Longevity Experts

On Friday, Longevity experts will discuss what you can do now for healthy Longevity including supplements, metformin, mTOR, NAD+, rapamycin, biohacking, fasting, biomarker tracking, monitoring apps, and more.